Tom Miller, Iambic Therapeutics CEO

Cor­rec­tion: Iambic says new AI mod­el bests Al­phaFold as pro­tein mod­els rock­et ahead

The sec­ond-gen­er­a­tion of Iambic Ther­a­peu­tics’ AI mod­el that pre­dicts the com­bined shape of pro­teins and small mol­e­cules out­per­forms Google Deep­Mind’s Al­phaFold, the San Diego biotech’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.